Literature DB >> 202255

A simple radioassay for angiotensin-converting enzyme.

J W Ryan, A Chung, C Ammons, M L Carlton.   

Abstract

Angiotensin-converting enzyme can be measured by the rate of release of 3H-labelled hippurate from p-[3H]benzoylglycylglycylglycine. The product is separable from the substrate by extraction of acidified reaction mixtures with ethyl acetate. Assay results for human serum angiotensin-converting enzyme can be obtained within 1.5 h of receipt of serum samples. Within the limits tested, the assay appears to be specific. However, interference by hitherto unrecognized enzymes of abnormal sera must be ruled out.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 202255      PMCID： PMC1183685          DOI： 10.1042/bj1670501

Source DB:  PubMed          Journal:  Biochem J        ISSN： 0264-6021            Impact factor:   3.857


  17 in total

1.  Kinetic properties of pulmonary angiotensin-converting enzyme. Hydrolysis of hippurylglycylglycine.

Authors:  F E Dorer; J R Kahn; K E Lentz; M Levine; L T Skeggs
Journal:  Biochim Biophys Acta       Date:  1976-03-11

2.  Synthesis and evaluation of (Des-Asp1)angiotensin I as a precursor for (Des-Asp1)angiotensin II ("Angiotensin III").

Authors:  B S Tsai; M J Peach; M C Khosla; F M Bumpus
Journal:  J Med Chem       Date:  1975-12       Impact factor: 7.446

3.  Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis.

Authors:  J Lieberman
Journal:  Am J Med       Date:  1975-09       Impact factor: 4.965

4.  A sensitive fluorimetric assay for serum angiotensin-converting enzyme.

Authors:  J Friedland; E Silverstein
Journal:  Am J Clin Pathol       Date:  1976-08       Impact factor: 2.493

5.  Formation of angiotensin III by angiotensin-converting enzyme.

Authors:  A T Chiu; J W Ryan; J M Stewart; F E Dorer
Journal:  Biochem J       Date:  1976-04-01       Impact factor: 3.857

6.  Studies on the angiotensin converting enzyme with different substrates.

Authors:  Y Piquilloud; A Reinharz; M Roth
Journal:  Biochim Biophys Acta       Date:  1970-04-22

7.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Authors:  M A Ondetti; B Rubin; D W Cushman
Journal:  Science       Date:  1977-04-22       Impact factor: 47.728

8.  The specificity and nature of serum-angiotensin-converting enzyme (serum ACE) elevations in sarcoidosis.

Authors:  J Lieberman
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

9.  Elevation of angiotensin-converting enzyme in granulomatous lymph nodes and serum in sarcoidosis: clinical and possible pathogenic significance.

Authors:  E Silverstein; J Friedland; H A Lyons; A Gourin
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

10.  The preparation and function of the hypertensin-converting enzyme.

Authors:  L T SKEGGS; J R KAHN; N P SHUMWAY
Journal:  J Exp Med       Date:  1956-03-01       Impact factor: 14.307
View more
  24 in total

1.  The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects.

Authors:  C L Brown; C I Backhouse; J C Grippat; J P Santoni
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Humoral effects of perindopril in essential hypertension.

Authors:  G A Sagnella; N D Markandu; D R Singer; M G Buckley; M A Miller; G A MacGregor
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

4.  The pharmacokinetics of perindopril in patients with liver cirrhosis.

Authors:  M Thiollet; C Funck-Brentano; J D Grangé; M Midavaine; G Resplandy; P Jaillon
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

5.  The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin.

Authors:  M A Rastegar; F Marchini; G Morazzoni; A Vegh; J G Papp; J R Parratt
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

6.  Fate of bradykinin-potentiating peptide 9a after intravenous injection.

Authors:  L C Martin; J W Ryan; G H Fisher; A Chung; M Epstein; J M Stewart
Journal:  Biochem J       Date:  1979-12-15       Impact factor: 3.857

7.  Human pulmonary endothelial cells in culture. Activities of cells from arteries and cells from veins.

Authors:  A R Johnson
Journal:  J Clin Invest       Date:  1980-04       Impact factor: 14.808

8.  Lung inflammation in sarcoidosis: comparison of serum angiotensin-converting enzyme levels with bronchoalveolar lavage and gallium-67 scanning assessment of the T lymphocyte alveolitis.

Authors:  C I Schoenberger; B R Line; B A Keogh; G W Hunninghake; R G Crystal
Journal:  Thorax       Date:  1982-01       Impact factor: 9.139

9.  Insulin sensitivity in normotensive subjects during angiotensin converting enzyme inhibition with fosinopril.

Authors:  Y Allemann; S Baumann; M Jost; P Ferrari; S Shaw; W Riesen; P Weidmann
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  Chronic antihypertensive treatment with captopril plus hydrochlorothiazide improves aortic distensibility in the spontaneously hypertensive rat.

Authors:  J M Chillon; C Capdeville-Atkinson; I Lartaud; J Guillou; P M Mertès; J Atkinson
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.